10 insiders reported 26 Form 4 transactions for Aprea Therapeutics, Inc. (APRE) over the past 18 months (most recent 2026-06-17). Recent activity: HENNEMAN JOHN B III (Director) Buy 3,135 shares, BIZZARI JEAN-PIERRE (Director) Buy 3,135 shares, Peters Richard (Director) Buy 3,135 shares, Grissinger Michael (Director) Buy 3,135 shares, Seizinger Bernd R. (Director) Buy 3,135 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | HENNEMAN JOHN B III | Director | Buy | 3,135 | $0 |
| 2026-06-17 | BIZZARI JEAN-PIERRE | Director | Buy | 3,135 | $0 |
| 2026-06-17 | Peters Richard | Director | Buy | 3,135 | $0 |
| 2026-06-17 | Grissinger Michael | Director | Buy | 3,135 | $0 |
| 2026-06-17 | Seizinger Bernd R. | Director | Buy | 3,135 | $0 |
| 2026-06-17 | Gruia Gabriela | Director | Buy | 3,135 | $0 |
| 2026-06-17 | Duey Marc | Director | Buy | 3,135 | $0 |
| 2026-06-17 | Pamukcu Rifat | Director | Buy | 3,135 | $0 |
| 2026-03-16 | Gilad Oren | President/CEO | Buy | 20,175 | $0 |
| 2026-03-16 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 10,095 | $0 |
| 2026-02-02 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,700 | $5,073 |
| 2026-02-02 | Gilad Oren | President/CEO | Buy | 28,100 | $25,009 |
| 2025-12-11 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,000 | $5,850 |
| 2025-12-11 | Duey Marc | Director | Buy | 21,459 | $25,107 |
| 2025-06-09 | HENNEMAN JOHN B III | Director | Buy | 1,045 | $0 |
| 2025-06-09 | Duey Marc | Director | Buy | 1,045 | $0 |
| 2025-06-09 | Grissinger Michael | Director | Buy | 1,045 | $0 |
| 2025-06-09 | Pamukcu Rifat | Director | Buy | 1,045 | $0 |
| 2025-06-09 | Gruia Gabriela | Director | Buy | 1,045 | $0 |
| 2025-06-09 | Seizinger Bernd R. | Director | Buy | 1,045 | $0 |
| 2025-06-09 | BIZZARI JEAN-PIERRE | Director | Buy | 1,045 | $0 |
| 2025-06-09 | Peters Richard | Director | Buy | 1,045 | $0 |
| 2025-04-04 | Gilad Oren | President/CEO | Buy | 3,003 | $5,616 |
| 2025-04-04 | Gilad Oren | President/CEO | Buy | 2,497 | $4,495 |
| 2025-03-31 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 3,365 | $0 |
Source: SEC Form 4 filings · as of 2026-06-17